Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer

Clinical trial and in vitro correlates

G. Batist, D. N. Carney, Kenneth H Cowan, S. R. Veach, M. Gilliom, P. A. Bunn, D. C. Ihde

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Treatment of patients with relapsed small-cell lung cancer (SCLC) has been uniformly unsuccessful. Recently, the combination of etoposide (VP-16) and cisplatin in this setting has been reported to result in up to 50% response rates. We treated 29 patients with relapsed SCLC with this combination and found only a 12% response rate. The discrepancy between our results and those of others is most likely due to differences in prior treatment of the patients, although the effect of dose and schedule modifications are considered. Our patients had received a six-drug regimen over a median of 7 months and had a median drug-free interval before this treatment of only three weeks. Evidence is presented that suggests that this aggressive initial therapy affected both host tolerance to further treatment and the development of tumor resistance at the cellular level.

Original languageEnglish (US)
Pages (from-to)982-986
Number of pages5
JournalJournal of Clinical Oncology
Volume4
Issue number6
DOIs
StatePublished - Jan 1 1986

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Clinical Trials
Therapeutics
Pharmaceutical Preparations
Appointments and Schedules
In Vitro Techniques
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer : Clinical trial and in vitro correlates. / Batist, G.; Carney, D. N.; Cowan, Kenneth H; Veach, S. R.; Gilliom, M.; Bunn, P. A.; Ihde, D. C.

In: Journal of Clinical Oncology, Vol. 4, No. 6, 01.01.1986, p. 982-986.

Research output: Contribution to journalArticle

Batist, G. ; Carney, D. N. ; Cowan, Kenneth H ; Veach, S. R. ; Gilliom, M. ; Bunn, P. A. ; Ihde, D. C. / Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer : Clinical trial and in vitro correlates. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 6. pp. 982-986.
@article{8c2d90b5d4fb46f7993a64c2fc6f5b22,
title = "Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: Clinical trial and in vitro correlates",
abstract = "Treatment of patients with relapsed small-cell lung cancer (SCLC) has been uniformly unsuccessful. Recently, the combination of etoposide (VP-16) and cisplatin in this setting has been reported to result in up to 50{\%} response rates. We treated 29 patients with relapsed SCLC with this combination and found only a 12{\%} response rate. The discrepancy between our results and those of others is most likely due to differences in prior treatment of the patients, although the effect of dose and schedule modifications are considered. Our patients had received a six-drug regimen over a median of 7 months and had a median drug-free interval before this treatment of only three weeks. Evidence is presented that suggests that this aggressive initial therapy affected both host tolerance to further treatment and the development of tumor resistance at the cellular level.",
author = "G. Batist and Carney, {D. N.} and Cowan, {Kenneth H} and Veach, {S. R.} and M. Gilliom and Bunn, {P. A.} and Ihde, {D. C.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1200/JCO.1986.4.6.982",
language = "English (US)",
volume = "4",
pages = "982--986",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer

T2 - Clinical trial and in vitro correlates

AU - Batist, G.

AU - Carney, D. N.

AU - Cowan, Kenneth H

AU - Veach, S. R.

AU - Gilliom, M.

AU - Bunn, P. A.

AU - Ihde, D. C.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Treatment of patients with relapsed small-cell lung cancer (SCLC) has been uniformly unsuccessful. Recently, the combination of etoposide (VP-16) and cisplatin in this setting has been reported to result in up to 50% response rates. We treated 29 patients with relapsed SCLC with this combination and found only a 12% response rate. The discrepancy between our results and those of others is most likely due to differences in prior treatment of the patients, although the effect of dose and schedule modifications are considered. Our patients had received a six-drug regimen over a median of 7 months and had a median drug-free interval before this treatment of only three weeks. Evidence is presented that suggests that this aggressive initial therapy affected both host tolerance to further treatment and the development of tumor resistance at the cellular level.

AB - Treatment of patients with relapsed small-cell lung cancer (SCLC) has been uniformly unsuccessful. Recently, the combination of etoposide (VP-16) and cisplatin in this setting has been reported to result in up to 50% response rates. We treated 29 patients with relapsed SCLC with this combination and found only a 12% response rate. The discrepancy between our results and those of others is most likely due to differences in prior treatment of the patients, although the effect of dose and schedule modifications are considered. Our patients had received a six-drug regimen over a median of 7 months and had a median drug-free interval before this treatment of only three weeks. Evidence is presented that suggests that this aggressive initial therapy affected both host tolerance to further treatment and the development of tumor resistance at the cellular level.

UR - http://www.scopus.com/inward/record.url?scp=0022453457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022453457&partnerID=8YFLogxK

U2 - 10.1200/JCO.1986.4.6.982

DO - 10.1200/JCO.1986.4.6.982

M3 - Article

VL - 4

SP - 982

EP - 986

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -